Therapeutic Potential of Cannabinoids in Psychosis

@article{Leweke2016TherapeuticPO,
  title={Therapeutic Potential of Cannabinoids in Psychosis},
  author={F. Leweke and Juliane K. Mueller and B. Lange and C. Rohleder},
  journal={Biological Psychiatry},
  year={2016},
  volume={79},
  pages={604-612}
}
Over recent years, the interest in the endocannabinoid system (ECS) as a new target for the treatment of schizophrenia has evolved. The ECS represents one of the most relevant neurotransmitter systems in the brain and mainly fulfills a homeostatic role in terms of neurotransmission but also with respect to inflammatory processes. Two main approaches to the modulation of endocannabinoid functioning have been chosen so far. First, the selective blockade or inverse agonism of the type 1… Expand
Role of the Endocannabinoid System in the Pathophysiology of Schizophrenia: Implications for Pharmacological Intervention
TLDR
Cannabidiol is a promising candidate as an effective and mechanistically different antipsychotic treatment with a favourable side-effect profile and the level of proof of safety and efficacy required to approve the therapeutic use of cannabidio in schizophrenia is currently lacking. Expand
Cannabidiol as a Potential New Type of an Antipsychotic. A Critical Review of the Evidence
TLDR
After some individual treatment attempts, the first randomized, double-blind controlled clinical trial demonstrated that in acute schizophrenia cannabidiol exerts antipsychotics properties comparable to the antipsychotic drug amisulpride while being accompanied by a superior, placebo-like side effect profile. Expand
Pregnenolone blocks cannabinoid-induced acute psychotic-like states in mice
TLDR
Test in mice the potential therapeutic use of pregnenolone against acute psychotic-like effects of Δ9-tetrahydrocannabinol, the main psychoactive component of cannabis found that it blocks a wide spectrum of THC-induced endophenotypes typically associated with psychotic- like states, including impairments in cognitive functions, somatosensory gating and social interaction. Expand
The Potential of Cannabidiol as a Treatment for Psychosis and Addiction: Who Benefits Most? A Systematic Review
TLDR
CBD, either as monotherapy or added to regular antipsychotic medication, improved symptoms in patients with schizophrenia, with particularly promising effects in the early stages of illness. Expand
Putative Role of Endocannabinoids in Schizophrenia
TLDR
Modulating endocannabinoids seems to be a new, promising pharmacological target for schizophrenia, and endoc cannabinoid-related fatty acid ethanolamides like oleoylethanolamide may play a role in energy metabolism and weight control, representing major topics in schizophrenia. Expand
Investigating the Role of the Endocannabinoid System in Early Psychosis
Accumulating evidence suggests that dysfunction within the endocannabinoid (eCB) system may play a role in psychosis. However, little is understood about how this may be related to the neurocognitiveExpand
The neuropharmacology of cannabinoid receptor ligands in central signaling pathways.
TLDR
The mechanism of action at the endocannabinoid system is described, mainly in the brain, and effects of cannabinoid ligands on other neurotransmitter systems will also be described, such as dopamine, serotonin, glutamate, noradrenaline, opioid and GABA. Expand
Role of Cannabidiol in the Therapeutic Intervention for Substance Use Disorders
TLDR
Preclinical and clinical reports regarding the effects of CBD on the regulation of the reinforcing, motivational and withdrawal-related effects of different drugs of abuse such as alcohol, opioids (morphine, heroin), cannabinoids, nicotine, and psychostimulants are reviewed. Expand
New drugs in psychiatry: focus on new pharmacological targets
TLDR
Drugs included here are new antipsychotic medications endowed with a preferential affinity at dopamine D3 receptor (cariprazine) or at glutamatergic or cannabinoid receptors, as well as vortioxetine, a drug approved for managing the cognitive deficits associated with major depression. Expand
Efficacy of Cannabidiol for Δ-9-Tetrahydrocannabinol-Induced Psychotic Symptoms, Schizophrenia, and Cannabis Use Disorders: A Narrative Review
TLDR
Available evidence suggests that CBD may attenuate both psychotic-like symptoms induced by THC in healthy volunteers and positive symptoms in individuals with schizophrenia, and preliminary data on the efficacy of CBD for cannabis use disorders show mixed findings. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 100 REFERENCES
Cannabinoids and schizophrenia
The discovery of the endocannabinoid system (ECS) has stimulated a growing body of psychiatric research focusing on the role of this system in major psychiatric disorders like schizophrenia.Expand
Anandamide dysfunction in prodromal and established psychosis.
  • F. Leweke
  • Medicine
  • Current pharmaceutical design
  • 2012
TLDR
A mini-review of the role of anandamide in schizophrenia is provided, investigating endogenous ligands to cannabinoid CB1-receptors such as an andamide both in cerebrospinal fluid and plasma of patients and controls. Expand
Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia
TLDR
It is suggested that inhibition of anandamide deactivation may contribute to the antipsychotic effects of cannabidiol potentially representing a completely new mechanism in the treatment of schizophrenia. Expand
Cannabis and psychiatric disorders: it is not only addiction
TLDR
It became apparent that cannabis use is not only frequent in patients suffering from BD, but that it also induces manic symptoms in this group and cannabinoid compounds could display a new class of medication, as suggested by the fatty acid amino hydrolase inhibitor URB597 in animal models. Expand
Effect of cannabidiol in a MK-801-rodent model of aspects of Schizophrenia
TLDR
In conclusion, cannabidiol showed both propsychotic activity and partial antipsychotic activity in an MK-801-induced model of aspects of schizophrenia, and showed potential towards inhibiting MK-802-induced social withdrawal. Expand
Molecular characterization of a peripheral receptor for cannabinoids
TLDR
The cloning of a receptor for cannabinoids is reported that is not expressed in the brain but rather in macrophages in the marginal zone of spleen, which helps clarify the non-psychoactive effects of cannabinoids. Expand
Pharmacological and molecular targets in the search for novel antipsychotics
The recent enthusiasm among clinicians for the so‐called "atypical antipsychotics" has both improved treatment for schizophrenic patients and provided a welcome stimulus for basic research onExpand
Cannabidiol monotherapy for treatment-resistant schizophrenia
TLDR
The preliminary data suggest that CBD monotherapy may not be effective for TRS, and patients with treatment-resistant schizophrenia should be switched to olanzapine for over 15 days. Expand
Cannabis-Associated Psychosis
TLDR
The recently suggested role of the endogenous cannabinoid system in schizophrenia not related to previous cannabinoid consumption introduces an additional perspective on the mechanism underlying cannabis-associated schizophrenia-like disorders, as well as on the effects of cannabis consumption in schizophrenia. Expand
A second endogenous cannabinoid that modulates long-term potentiation
TLDR
2-AG activates neuronal cannabinoid receptors as a full agonist, and prevents the induction of long-term potentiation at CA3–CA1 synapses, indicating that 2-AG is a second endogenous cannabinoid ligand in the central nervous system. Expand
...
1
2
3
4
5
...